Plasma Metabolic Biomarkers for Multi-Cancer Diagnosis
Identification and Validation of Plasma Diagnostic Biomarkers for Multi-Cancer Based on Metabolomics: A Multi-Center Clinical Research and Validation Trial
Beijing Friendship Hospital
2,700 participants
Mar 29, 2024
OBSERVATIONAL
Conditions
Summary
The aim of this observational study is to comprehensively analyze the metabolites in plasma samples from multi-cancer patients using advanced mass spectrometry detection technology, in conjunction with metabolomics approaches. The goal is to construct a plasma metabolite database for multi-cancer patients. Simultaneously, we will delve into the exploration and validation of a series of metabolic biomarkers for early multi-cancer diagnosis. The objective is to establish a safer, more convenient, and more sensitive early screening method, thereby providing a reliable scientific foundation and critical evidence for improving the early diagnostic process for individuals at high risk of multi-cancer.
Eligibility
Inclusion Criteria8
- Multi-Cancer Group:
- Patients with a confirmed diagnosis based on the clinical "gold standard".
- Collection of plasma samples prior to treatment.
- Availability of complete clinical data.
- Control Group:
- Individuals with no abnormalities in routine physical examinations and relevant clinical tests.
- Age ≥ 45 years.
- Availability of complete clinical data.
Exclusion Criteria12
- Previous reception of anti-tumor treatments (including radiotherapy, chemotherapy, etc.) before blood collection.
- Coexistence of other systemic tumors.
- Absence of plasma sample collection before treatment.
- Pregnancy status.
- No clear evidence of histopathological diagnosis (not applicable to the control group based on this criterion).
- Patients with severe acute infections.
- Patients with severe anemia.
- Patients with severe liver or kidney dysfunction.
- Patients with autoimmune deficiency diseases.
- Patients with Hyperlipidemia.
- Patients received contrast agent injection before blood draw.
- Patients with psychiatric disorders.
Locations(4)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06363123